Biggest stock movers Monday: SRPT, CSCO, and more

Stock futures edged up early Monday morning amidst rising tensions between Israel and Iran, which led to a spike in oil prices and heightened investor concerns regarding the global economic outlook.

Here are some of Monday’s biggest stock movers:

Biggest stock gainers

• Cisco Systems (NASDAQ:CSCO) +2% – Shares rose after Deutsche Bank upgraded the stock to Buy from Hold, citing increased visibility into “durable mid-single-digit growth in the coming years.” Analyst Matthew Niknam pointed to AI tailwinds, favorable near-term competition in Networking, and improved scale in Security as key drivers. He also noted that growth in higher-margin revenue and Cisco’s extensive supply chain position the company well to absorb tariffs and reinvest in expansion. The firm set a price target of $73, implying a 14% upside from the previous close.

• EchoStar (NASDAQ:SATS) +52% – Shares surged on reports that President Trump intervened to help resolve tensions between the FCC and EchoStar over its spectrum licenses. According to reports, EchoStar Chairman Charlie Ergen met with FCC Commissioner Brendan Carr, who warned that the company risked losing spectrum licenses unless it began selling them. The FCC had recently threatened a probe into EchoStar’s slow deployment of its 5G network, accusing the firm of “spectrum warehousing.” The regulatory pressure, intensified by competition from SpaceX’s Starlink, had reportedly pushed EchoStar to consider Chapter 11 bankruptcy to shield its Boost Mobile business.

Biggest stock losers

• Sarepta Therapeutics (NASDAQ:SRPT) -26% – Shares plunged after the company reported a second patient death linked to its Duchenne muscular dystrophy gene therapy, Elevidys. The latest fatality, involving a non-ambulatory patient who suffered acute liver failure, follows a similar case in March. In response, Sarepta has paused the clinical trial, halted Elevidys shipments for non-ambulatory patients, and is weighing enhanced immunosuppression protocols. The developments have intensified scrutiny around Elevidys and the FDA’s approval process.